related documents
- Demonstrated safety with daily subcutaneous (SC) injections of Kineret (R) (Anakinra "C recombinant interleukin-1 receptor antagonist) in a standard practice population Conferences
- Efficacy and safety of adalimumab (HUMIRA (R)) in Canadian clinical practice. A comparison of the Canadian and the European practice: The canact and the react trial to Conferences
- Patient function improved as measured by the health assessment questionnaire - Disability index (HAQ-DI), following daily subcutaneous (SC) injections of kineret; (Anakinra-recombinant interleukin-1 receptor antagonist) in a standard practice populatio Conferences
- Resource utilization and costs of rheumatoid arthritis in Brazil Conferences
- Resource utilization in postmenopausal osteoporosis Conferences
- Twelve-month follow-up results for the etanercept community health outcomes [ECHO] study Conferences